Beigene Ltd Stock Price, News & Analysis

BeiGene announced promising results from the interim analysis of the Phase 3 SEQUOIA trial for BRUKINSA in treatment-naïve chronic lymphocytic leukemia (CLL), showing superior progression-free survival (PFS) compared to bendamustine plus rituximab. The 24-month PFS rate for BRUKINSA was 85.5%, significantly higher than 69.5% for the control group. Consistent safety results were noted, with lower rates of adverse events like atrial fibrillation. Preliminary data for BRUKINSA combined with venetoclax in high-risk CLL patients also showed high efficacy and safety.

BeiGene presented new safety and efficacy data for BRUKINSA (zanubrutinib) at the 63rd ASH Annual Meeting. Results from a Phase 2 trial showed that 93.8% of patients maintained disease control, while 64.1% improved their response. Treatment was well-tolerated, with 59.6% of prior ibrutinib users and 70.0% of acalabrutinib users not experiencing recurrence of intolerable adverse events. BRUKINSA's design aims to optimize kinase selectivity, thus reducing off-target effects. These findings reinforce BRUKINSA's potential for B-cell malignancies patients intolerant to other BTK inhibitors.

BeiGene announced results from the RATIONALE 309 trial, where its drug tislelizumab significantly improved progression-free survival (PFS) in patients with recurrent or metastatic nasopharyngeal cancer (RM-NPC) compared to placebo and chemotherapy. The median PFS was 9.2 months for the drug combination versus 7.4 months for placebo, demonstrating a notable survival benefit across subgroups. The safety profile was consistent with known risks, and a supplemental biologics license application is under review in China for this indication.

BeiGene (NASDAQ:BGNE) has announced the addition of three of its innovative oncology medicines to China's National Reimbursement Drug List (NRDL), effective January 1, 2022. The newly included medicines are anti-PD-1 antibody tislelizumab in three new indications, the BTK inhibitor BRUKINSA in one new indication, and the PARP inhibitor pamiparib for recurrent advanced ovarian cancer. This move aims to enhance patient access to effective cancer treatments while reducing financial burdens on families.

BeiGene, Ltd. (NASDAQ: BGNE) and EUSA Pharma have announced NMPA approval for SYLVANT® (siltuximab) in treating adult patients with idiopathic multicentric Castleman disease (iMCD) in China. This approval highlights the companies' collaboration and provides a vital new treatment option for patients suffering from this rare, debilitating disease. The approval is supported by a Phase 2 trial demonstrating significant efficacy with a durable response rate of 34% versus 0% for placebo. SYLVANT® has already been approved in multiple regions, and BeiGene plans to launch it in 2022.

BeiGene (NASDAQ: BGNE) announced that results from the RATIONALE 309 trial evaluating tislelizumab with chemotherapy in nasopharyngeal cancer will be presented at the ESMO IO Congress from December 8-11, 2021. This interim analysis supports a regulatory submission in China for recurrent or metastatic nasopharyngeal cancer. Additionally, data from trials involving tislelizumab combined with the kinase inhibitor sitravatinib in melanoma and ovarian cancer will be shared, highlighting the company's commitment to developing effective immunotherapies and addressing unmet medical needs globally.

BeiGene, Ltd. announced the pricing of its initial public offering (STAR Offering) on the STAR Market of the Shanghai Stock Exchange, offering 115,055,260 ordinary shares, representing 8.62% of its outstanding shares. The shares are priced at RMB192.60 each, yielding gross proceeds of approximately RMB22.2 billion (US$3.5 billion). The funds will support research, development, and expansion in China. The shares are expected to trade on December 15, 2021. An over-allotment option for 17,258,000 additional shares could increase the offering to 132,313,260 shares.

BeiGene announced the European Commission's approval of BRUKINSA (zanubrutinib) for treating Waldenström’s macroglobulinemia (WM) patients who have undergone prior therapy or are unsuitable for chemo-immunotherapy. This approval spans all EU member states, Iceland, and Norway. The decision is based on the Phase 3 ASPEN trial, showing BRUKINSA's safety advantages over ibrutinib despite not meeting the primary endpoint for statistical superiority. BeiGene aims to expedite access to this therapy across Europe.

BeiGene, Ltd. announced its initial public offering (IPO) on the STAR Market of the Shanghai Stock Exchange, offering 115,055,260 ordinary shares, representing 8.62% of its total shares as of October 31, 2021. The STAR Offering will be conducted for investors in the People's Republic of China (PRC) with additional options for 17,258,000 shares. Proceeds will fund R&D, the construction of centers in China, and sales expansion. The offering is subject to market conditions and regulatory approvals and will not involve the U.S. market.